MARKERS OF INFLAMMATION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND CARDIOVASCULAR PATHOLOGY

Objective: to estimate the levels of high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-α), and soluble TNF-α receptor type 1 (sTNF-R1) in patients with antiphospholipid syndrome (APS) and their association with cardiovascular pathology. Subjects and methods. Ninety-six patients, including 52 with primary APS and 44 with systemic lupus erythematosus and APS, were examined. A control group comprised 29 individuals without the signs of autoimmune disease. The levels of hsCRP, IL-6, TNF-α, sTNF-R1, antiphospholipid antibodies, and plasma lipids were studied; ultrasonography measuring the carotid intima-media complex (IMC), electrocardiography (ECG), echocardiography, and Holter ECG monitoring were made.
Results. The concentrations of hsCRP, IL-6, TNF-α, and sTNF-R1 were significantly higher in the patient groups than in the controls (p < 0.05). Elevated sTNF-R1 concentrations were more common in angina pectoris than in its absence (OR = 2.13; 95% CI [1.51; 2.99]; p < 0.001). In patients with damage to the valvular apparatus, IL-6, TNF-α, and sTNF-R1 concentrations were significantly higher than those in patients without the defects (p = 0.02, 0.02, and 0.01, respectively). The levels of TNF-α and sTNF-R1 were significantly higher in hypertensive patients than those in non-hypertensives (p = 0.002 and p < 0.001; respectively). The blood concentration of TNF-α was significantly higher in patients having the risk factors and subclinical signs of atherosclerosis that that in those without the signs and risk factors of atherosclerosis (p < 0.05). Analysis showed a direct correlation between the levels of TNF-α, hsCRP, IL-6, and sTNF-R1 and an inverse correlation of those of IL-6 and TNF-α with the duration of posttrombosis (p < 0.05). A correlation was found between the concentrations of TNF-α and sTNF-R1, and IMC of the great arteries, as well as the cumulative coronary risk (p < 0.05). Conclusion. In patients with APS, the levels of all the test markers were significantly higher than those in the controls. An association was revealed between the values of TNF-α and sTNF-R1 and the risk factors and subclinical signs of atherosclerosis.

high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-a, soluble TNF-α receptor type 1, antiphospholipid syndrome, thrombosis, atherosclerosis

1. <div><p>Насонов Е.Л. Антифосфолипидный синдром. М.: Литтерра, 2004; 379 c.</p><p>Giannakopoulos B., Passam F., Rahgozar S. et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-30.</p><p>Chen P.P. The novel autoantigens and prothrombotic mechanisms for antiphospholipid antibodies. Lupus. The 8th International Congress on SLE 2007; 16: 20-2.</p><p>Насонов Е.Л. Проблемы атеротромбоза в ревматологии. Вестн. РАМН 2003; 7: 6-11.</p><p>Shoenfeld Y., Harats D., Wick G., eds. Atherosclerosis and autoimmunity. Amsterdam - Lausanne - New York - Oxford - Shannon - Singapure - Tokyo: Elsevier, 2001; 370 p.</p><p>Jimenez S., Garcia-Criado M.A., Tassies D. et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005; 44(6)756-61.</p><p>Ames P.R.J., Tommasino C., Brancaccio V. et al. C-Reactive protein in primary antiphospholipid syndrome. J Rheumatol 2007; 34(3): 650-1.</p><p>Sailer T., Vormittag R., Pabinger I. et al. Inflammation in patients with lupus anticoagulant and implications for thrombosis. J Rheumatol 2005; 326: 462-8.</p><p>Hunt B.J. The endothelium in atherogenesis. Lupus 2000; 9: 189-93.</p><p>Meroni P.L. Endothelial cell perturbation by antiphospholipid antibodies in systemic lupus erythematosus. Lupus. The 8th International Congress on SLE 2007; 16: 17-9.</p><p>Pierangeli S.S. New targeted therapies for treatment of thrombosis in antiphospholipid syndrome: lessons from In Vitro and In Vivo studies. Lupus. The 8th International Congress on SLE 2007; 16: 19-20.</p><p>Pierangeli S.S., Harris E.N. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells. Lupus 2003; 12(7): 539-45.</p><p>Shoenfeld Y., Gerli R., Doria A. et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005; 112: 3337-47.</p><p>Szekanecz Z., Shoenfeld Y. Lupus and cardiovascular disease: the facts. Lupus 2006; 15: 3-10.</p><p>Girn H.R.S., Orsi N.M., Homer- Vanniasinkam S. An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease. Vasc Med 2007; 12: 299-309.</p><p>Aringer M., Smolen J.S. The role of tumor necrosis factor-alpha in systemic lupus erythematosus. Arthr Res Ther 2008; 10: 202-10.</p><p>Berman J., Girardi G., Salmon J.E. TNF-α is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. J Immunol 2005; 174: 485-90.</p><p>Myakis S., Lockshin M.D., Atsumi A. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006; 4: 295-306.</p><p>Hochberg M.C. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 1997; 40: 1725.</p><p>Тихонова Т.Л., Мач Э.С., Широкова И.Е. и др. Антифосфолипидный синдром и экзогенные факторы риска тромбозов. Тер. арх. 2004; 76(11): 71-4.</p><p>Barter P., Brewer B., Brown G. et al. Pocket guide to prevention of coronary heart disease. Downloaded in January 2003 from www.chd-taskforce.com &lt;http://www.chd-taskforce.com&gt;</p><p>Перова Н.В. Суммарный коронарный риск ИБС и показания к лечению гиперхолестеринемии (применение Европейских рекомендаций к российским условиям). Кардиология 1996; 3: 47-53.</p><p>Александрова Е.Л., Насонов Е.Л., Ковалев В.Ю. Количественный иммуноферментный метод определения антител к кардиолипину в сыворотке крови. Клин. ревматол. 1995; 4: 35-9.</p><p>Haward G., Sharrett A.R., Heiss G. et al. Carotid artery intima-media thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators, Stroke 1993; 24: 1297-304.</p><p>Kazmierski R., Watala C., Lukasik M. et al. Common carotid artery remodeling studied by sonomorphological criteria. J Neuroimaging 2004; 14(3): 258-64.</p><p>Ianuzzi A., Michele M.D., Panico S. et al. Radical-Trapping Activity, Blood Pressure and Carotid Enlargement in women. Hypertension 2003; 41: 289-96.</p><p>Насонов Е.Л., Панюкова Е.Н., Александрова Е.Н. С-реактивный белок - маркер воспаления при атеросклерозе (новые данные). Кардиология 2002; 7: 53-9.</p><p>Ridker P.M. Clinical application of C- reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.</p><p>Dropinski J., Szczeklik W., Rubis P. et al. Antiphospholipid antibodies and carotid artery intima-media thickness in young survivors of myocardial infarction. Med Sci Monit 2003; 9(4): 105-9.</p><p>Osula S., Bell G.M., Hornung R.S. Acute myocardial infarction in young adults: causes and management. Postgrad Med J 2002; 78: 27-30.</p><p>Forastiero R.R., Martinuzzo M.E., De Larranaga G.F. Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies. Lupus 2005; 14: 129-36.</p><p>Aringer M., Smolen J.S. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004; 13: 344-7.</p><p>Farzaneh-Far A., Roman M.J., Lockshin M.D. et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthr Rheum 2006; 54(12): 3918-25.</p><p>Asanuma Y., Chung C.P., Oeser A. et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33(3): 539-45.</p><p>Svenungsson E., Gunnarsson I., Fei G.- Z. et al. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor α/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthr Rheum 2003; 48(9): 2533-40.</p><p>Ильина А.Е., Клюквина Н.Г., Александрова Е.Н. и др. Растворимые рецепторы α-фактора некроза опухолей: связь с атеросклеротическим поражением сосудов при системной красной волчанке у мужчин. Тер. арх. 2006; 6: 20-4.</p><p>Elkind M.S., Cheng J., Boden-Albala B. et al. Tumor necrosis factor receptor levels are associated with carotid atherosclerosis. Stroke 2002; 33: 31-7.</p><p>Gustafsson G. Risk factors for atherosclerosis in SLE. Lupus. The 8th International Congress on SLE 2007; 16: 293.</p><p>Rho Y.H., Chung C.P., Oeser A. et al. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008; 35(9): 1789-94.</p><p>Бородин А.Г., Баранов А.А., Клюквина Н.Г. и др. Клинико-патогенетическое значение фактора некроза опухоли- альфа при системной красной волчанке. Тер. арх. 2002; 5: 32-5.</p><p>Кричевская О.А., Клюквина Н.Г., Александрова Е.Н. и др. Клиническое значение растворимых рецепторов фактора некроза опухоли a у больных системной красной волчанкой. Клин. мед. 2004; 10: 51-5.</p></div><br />